Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 10/20 | 0.58 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.51 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.50 |
| ▸ | ACTR2 | P61160 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2932864 | 0.89 | CCR1 (0.58) | CCR1PDK1PDK2PDK3PDK4 | |
| SCHEMBL6256307 | 0.89 | CCR1 (0.58) | CCR1PDK1PDK2PDK3PDK4 | |
| SCHEMBL5971697 | 0.89 | CCR1 (0.58) | CCR1PDK1PDK2PDK3PDK4 | |
| SCHEMBL6077406 | 0.88 | CCR1 (0.57) | CCR1PDK1PDK2PDK3PDK4 | |
| SCHEMBL20274121 | 0.88 | CCR1 (0.50) | CCR1PDK1PDK2PDK3PDK4 | |
| SCHEMBL6246788 | 0.84 | CCR1 (0.61) | CCR1PDK1PDK2PDK3PDK4 | |
| SCHEMBL5066103 | 0.84 | CCR1 (0.67) | CCR1PDK1PDK2PDK3PDK4 | |
| SCHEMBL5066100 | 0.84 | CCR1 (0.67) | CCR1PDK1PDK2PDK3PDK4 | |
| SCHEMBL5066097 | 0.84 | CCR1 (0.67) | CCR1PDK1PDK2PDK3PDK4 | |
| SCHEMBL5056092 | 0.81 | CCR1 (0.66) | CCR1PDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098212-B2 | Piperazine derivatives | BLUMBERG LAURA C | 2006-08-29 | — | — | US | disclosed |
| US-6974817-B2 | CCR1 receptor antagonists; inhibitors of MIP-1 alpha (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells; macrophage inflammatory protein (MIP) | PFIZER INC. (US) | 2005-12-13 | — | — | US | disclosed |
| US-20050250790-A1 | Novel sulfonic acid derivatives | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| EP-1583533-A1 | USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1572704-A1 | PHOSPHORUS-CONTAINING PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1558258-A1 | USE OF PIPERAZINE SULFONIC ACID DERIVATIVES AS CCR1 ANTAGONISTS FOR THE TREATMENT OF FIBROSIS, ALZHEIMER DISEASE AND OTHER DISORDERS | Pfizer Products Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| EP-1438298-A1 | PIPERAZINE DERIVATIVES WITH CCR1 RECEPTOR ANTAGONIST ACTIVITY | Pfizer Products Inc. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040127465-A1 | Novel phosphorus-containing derivatives | PFIZER INC | 2004-07-01 | — | — | US | disclosed |
| WO-2004055031-A1 | PHOSPHORUS-CONTAINING PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2004-07-01 | — | — | WO | disclosed |
| EP-1430041-A2 | NOVEL SULFONIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20040116441-A1 | Methods of using sulfonic acid derivatives | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| US-20040092529-A1 | Methods of using piperazine derivatives | PFIZER INC | 2004-05-13 | — | — | US | disclosed |
| WO-2004039377-A1 | USE OF PIPERAZINE SULFONIC ACID DERIVATIVES AS CCR1 ANTAGONISTS FOR THE TREATMENT OF FIBROSIS, ALZHEIMER DISEASE AND OTHER DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004039376-A1 | USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20040034034-A1 | Novel piperazine derivatives | BLUMBERG LAURA C (US) | 2004-02-19 | — | — | US | disclosed |
| US-20030083335-A1 | Novel sulfonic acid derivatives | HAYWARD MATTHEW M (US) | 2003-05-01 | — | — | US | disclosed |
| WO-2003035627-A1 | PIPERAZINE DERIVATIVES WITH CCR1 RECEPTOR ANTAGONIST ACTIVITY | PFIZER PRODUCTS INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2002102787-A2 | NOVEL SULFONIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092529-A1 | Methods of using piperazine derivatives | CCR1, CCR3, CCR5 | CCR1 1/4885PDK1 2128/4885PDK2 1801/4885 |
| US-20050250790-A1 | Novel sulfonic acid derivatives | MSR1, MYD88, CXCR2 | CCR1 4/4885PDK1 1591/4885PDK2 1205/4885 |
| US-20040127465-A1 | Novel phosphorus-containing derivatives | SLC34A2, SLC34A1, SLC20A1 | CCR1 39/4885PDK1 516/4885PDK2 939/4885 |
| US-20040034034-A1 | Novel piperazine derivatives | CCR1, CCRL2, CCR5 | CCR1 1/4885PDK1 2065/4885PDK2 1923/4885 |
| US-20030083335-A1 | Novel sulfonic acid derivatives | CCR1, MSR1, CXCR1 | CCR1 1/4885PDK1 2165/4885PDK2 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.